Tvardi Therapeutics (TVRD) Enterprise Value (2016 - 2025)
Tvardi Therapeutics' Enterprise Value history spans 13 years, with the latest figure at -$30.8 million for Q4 2025.
- On a quarterly basis, Enterprise Value rose 2.47% to -$30.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$30.8 million, a 2.47% increase, with the full-year FY2025 number at -$30.8 million, up 2.47% from a year prior.
- Enterprise Value hit -$30.8 million in Q4 2025 for Tvardi Therapeutics, up from -$36.4 million in the prior quarter.
- Over the last five years, Enterprise Value for TVRD hit a ceiling of -$30.8 million in Q4 2025 and a floor of -$171.6 million in Q1 2021.
- Historically, Enterprise Value has averaged -$94.9 million across 5 years, with a median of -$86.6 million in 2023.
- The widest YoY moves for Enterprise Value: up 68.62% in 2024, down 45.97% in 2024.
- Tracing TVRD's Enterprise Value over 5 years: stood at -$167.0 million in 2021, then increased by 12.95% to -$145.4 million in 2022, then soared by 30.7% to -$100.8 million in 2023, then skyrocketed by 68.62% to -$31.6 million in 2024, then increased by 2.47% to -$30.8 million in 2025.
- Business Quant data shows Enterprise Value for TVRD at -$30.8 million in Q4 2025, -$36.4 million in Q3 2025, and -$40.9 million in Q2 2025.